bpc-157 fda approval status safety advisory committee votes to add popular peptide to drug compounding list BPC-157 and TB-500: Unapproved and

Fiolet T, Kherabi Y, MacDonald CJ, Ghosn J, Peiffer-Smadja N

It's important to note that BPC-157 is not a treatment for injuries

Common side effects: AOD 9604 has essentially none (indistinguishable from placebo)

AOD-9604 Peptide Synthesized and Lyophilized in Canada by Koi Peptides Domestic Synthesis at a Canadian Facility Assembly of the 16-residue chain is carried out by solid-phase peptide synthesis at a Canadian manufacturing partner, with the Cys7-Cys14 disulfide bond formed during the oxidation step before final purification

A mathematical model for relating the drug sensitivity of tumor to their spontaneous mutation rate